ORADUR-Methylphenidate is an investigational formulation of methylphenidate being evaluated for its ability to provide once-daily dosing while resisting certain common forms of drug tampering. Methylphenidate, the active ingredient, is approved and widely-prescribed for the treatment of attention deficit hyperactivity disorder (ADHD).
Methylphenidate exposes patients to risks of addiction, abuse, and misuse even when abuse-deterrent properties are present. ORADUR-Methylphenidate is an investigational drug and has not been approved by the FDA for marketing in the U.S. for any indication.
ORADUR-Methylphenidate is being studied for its ability to:
- Allow once-daily dosing with a rapid onset of action and small capsule size
- Deter the most common methods of abuse (snorting, smoking, injecting, chewing, and dissolving in drinks)
Methylphenidate exposes patients to risks of addiction, abuse, and misuse even when abuse-deterrent properties are present. ORADUR-Methylphenidate is an investigational product and has not been approved by the FDA for marketing in the U.S. for any indication.
Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral condition estimated to affect over 5 million (approximately 9%) of U.S. children ages 3-17, according to the U.S. Department of Health and Human Services. The principal characteristics of ADHD are inattention, hyperactivity, and impulsivity. The condition typically manifests during childhood, and many patients continue to be affected as adults. Over 50% of children with ADHD are medically treated, with stimulants such as amphetamine and methylphenidate commonly prescribed as first-line agents. U.S. sales of ADHD treatments were approximately $10.4 billion in 2016. The 2010 National Survey on Drug Use and Health estimates that 1.1 million Americans over the age of 12 abuse stimulants for euphoric highs and increased performance or wakefulness.
ORADUR-Methylphenidate is an investigational product and has not been approved by the FDA for marketing in the U.S. for any indication.
Orient Pharma, our licensee in certain markets, has completed enrollment of a Phase 3 study in Taiwan and anticipates obtaining top-line results in the second quarter of 2017.
DURECT has licensed the development and commercialization rights for ORADUR-Methylphenidate to Orient Pharma Co., Ltd. (Orient Pharma) for certain defined Asian and South Pacific countries. DURECT retains rights to North America, Europe, Japan, and all other countries not specifically licensed to Orient Pharma. For a description of the associated terms, please see Collaborations.
There are risks and uncertainties associated with our business. Please see our most recent SEC filings (10-K or 10-Q) for a complete description of these risks and uncertainties, which are incorporated herein by reference.